$REFR
RESEARCH FRONTIERS INC Stock $refr

$refr Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222030341 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$129.9K	$150.4K	$723.5K
YoY Change	-38.87%	-79.21%	325.57%
Cost Of Revenue	$785.3K	$487.5K	$571.0K
YoY Change	-4.48%	-14.63%	21.49%
Gross Profit	-$655.4K	-$337.0K	$152.5K
YoY Change	7.5%	-321.08%	-149.18%
Gross Profit Margin	-504.53%	-224.03%	21.07%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$164.7K	$149.2K	$135.2K
YoY Change	3.07%	10.31%	-3.41%
% of Gross Profit			88.7%
Depreciation & Amortization	$7.230K	$7.200K	-$6.100K
YoY Change	456.15%	-218.03%	-79.67%
% of Gross Profit			-4.0%
Operating Expenses	$164.7K	$636.6K	$135.2K
YoY Change	3.07%	370.81%	-3.41%
Operating Profit	-$820.1K	-$486.2K	$17.23K
YoY Change	6.58%	-2921.76%	-103.83%
Interest Expense	$4.650K	$2.460K	$4.390K
YoY Change	-135.02%	-43.96%
% of Operating Profit			25.48%
Other Income/Expense, Net
YoY Change
Pretax Income	-$815.4K	-$483.7K	$21.61K
YoY Change	4.18%	-2338.45%	-105.03%
Income Tax
% Of Pretax Income
Net Earnings	-$815.4K	-$483.7K	$21.61K
YoY Change	4.18%	-2338.45%	-105.03%
Net Earnings / Revenue	-627.74%	-321.54%	2.99%
Basic Earnings Per Share		-$0.02	$0.00
Diluted Earnings Per Share	-$0.02	-$15.20K	$682.80
COMMON SHARES
Basic Shares Outstanding	33.15M shares	31.65M shares	31.65M shares
Diluted Shares Outstanding		31.83M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.231M	$4.800M	$2.985M
YoY Change	39.86%	60.83%	-45.14%
Cash & Equivalents	$4.200M	$4.800M	$2.985M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$101.0K	$166.6K	$158.7K
YoY Change	8.65%	4.96%	44.27%
Inventory
Prepaid Expenses
Receivables	$589.6K	$534.5K	$1.353M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.921M	$5.499M	$4.496M
YoY Change	24.61%	22.31%	-26.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$65.39K	$72.56K	$606.8K
YoY Change	-29.66%	-88.04%	-16.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.07K	$33.57K	$33.57K
YoY Change	67.03%	-0.01%	11.9%
Total Long-Term Assets	$445.0K	$466.3K	$640.4K
YoY Change	-25.38%	-27.18%	-15.74%
TOTAL ASSETS
Total Short-Term Assets	$4.921M	$5.499M	$4.496M
Total Long-Term Assets	$445.0K	$466.3K	$640.4K
Total Assets	$5.366M	$5.966M	$5.137M
YoY Change	18.05%	16.14%	-25.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$71.08K	$38.01K	$33.57K
YoY Change	6.95%	13.23%	-32.86%
Accrued Expenses	$34.38K	$32.95K	$229.2K
YoY Change	-30.39%	-85.62%	4.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$301.9K	$267.7K	$276.0K
YoY Change	1.32%	-3.01%	-4.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$267.7K	$317.8K	$511.0K
YoY Change	-42.32%	-37.81%	-25.94%
Total Long-Term Liabilities	$267.7K	$317.8K	$511.0K
YoY Change	-42.32%	-37.81%	-25.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$301.9K	$267.7K	$276.0K
Total Long-Term Liabilities	$267.7K	$317.8K	$511.0K
Total Liabilities	$569.6K	$585.5K	$787.0K
YoY Change	-25.26%	-25.6%	-19.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$122.4M	-$121.5M
YoY Change	2.27%
Common Stock	$127.2M	$126.9M
YoY Change	2.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.800M	$5.400M	$4.350M
YoY Change
Total Liabilities & Shareholders Equity	$5.366M	$5.966M	$5.137M
YoY Change	18.05%	16.14%	-25.12%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$815.4K	-$483.7K	$21.61K
YoY Change	4.18%	-2338.45%	-105.03%
Depreciation, Depletion And Amortization	$7.230K	$7.200K	-$6.100K
YoY Change	456.15%	-218.03%	-79.67%
Cash From Operating Activities	-$567.2K	-$535.8K	-$488.6K
YoY Change	-920.81%	9.66%	22.15%
INVESTING ACTIVITIES
Capital Expenditures	$50.00	-$150.00	-$30.00
YoY Change	-145.45%	400.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$3.134M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$50.00	-$150.00	$3.134M
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	3.450M	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-567.2K	-535.8K	-488.6K
Cash From Investing Activities	-50.00	-150.0	3.134M
Cash From Financing Activities	0.000	3.450M	0.000
Net Change In Cash	-567.2K	2.914M	2.645M
YoY Change	-79.1%	10.17%	-761.25%
FREE CASH FLOW
Cash From Operating Activities	-$567.2K	-$535.8K	-$488.6K
Capital Expenditures	$50.00	-$150.00	-$30.00
Free Cash Flow	-$567.2K	-$535.6K	-$488.6K
YoY Change	-919.58%	9.63%	22.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	REFR	Royalties Receivable Net Current RoyaltiesReceivableNetCurrent	534529	usd
CY2021Q4	REFR	Royalties Receivable Net Current RoyaltiesReceivableNetCurrent	831636	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	166571	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92931	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	5499250	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3949642	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	72556	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	92954	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	360164	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	469824	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33567	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33567	usd
CY2022Q3	us-gaap	Assets Assets	5965537	usd
CY2021Q4	us-gaap	Assets Assets	4545987	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	193182	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	182091	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	38010	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	66460	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32946	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49385	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	3586	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	267724	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	297936	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	317805	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	464128	usd
CY2022Q3	us-gaap	Liabilities Liabilities	585529	usd
CY2021Q4	us-gaap	Liabilities Liabilities	762064	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33150396	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33150396	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31650396	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31650396	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	3315	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3165	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	126917736	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	123467886	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121541043	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119687128	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5380008	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3783923	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5965537	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4545987	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	409783	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1050526	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	150443	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	723465	usd
	us-gaap	Other General Expense OtherGeneralExpense	1770414	usd
	us-gaap	Other General Expense OtherGeneralExpense	1699698	usd
CY2022Q3	us-gaap	Other General Expense OtherGeneralExpense	487476	usd
CY2021Q3	us-gaap	Other General Expense OtherGeneralExpense	571024	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	444413	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	420203	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149156	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	135215	usd
	us-gaap	Operating Expenses OperatingExpenses	2214827	usd
	us-gaap	Operating Expenses OperatingExpenses	2119901	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	636632	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	706239	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1805044	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1069375	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-486189	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	17226	usd
	REFR	Net Investment Income Loss NetInvestmentIncomeLoss	-48871	usd
	REFR	Net Investment Income Loss NetInvestmentIncomeLoss	5747	usd
CY2022Q3	REFR	Net Investment Income Loss NetInvestmentIncomeLoss	2460	usd
CY2021Q3	REFR	Net Investment Income Loss NetInvestmentIncomeLoss	4388	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1853915	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1063628	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-483729	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	21614	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31710179	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31645227	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31829744	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31650396	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5327005	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86262	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1063628	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	4349639	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3783923	usd
	REFR	Stock Issued During Period Value Common Stock And Warrants StockIssuedDuringPeriodValueCommonStockAndWarrants	3450000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1853915	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5380008	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	4328025	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	21614	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	4349639	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2413737	usd
CY2022Q3	REFR	Stock Issued During Period Value Common Stock And Warrants StockIssuedDuringPeriodValueCommonStockAndWarrants	3450000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-483729	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-483729	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5380008	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1853915	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1063628	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21614	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	22414	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-60143	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5545	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	151772	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	109660	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	109963	usd
	REFR	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	-145335	usd
	REFR	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	754679	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	73640	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	102183	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-44889	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	24959	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3586	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	13304	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-135232	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-123539	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1615566	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1867844	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1216	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	966	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3433633	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2694968	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	650000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2693752	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2784599	usd
	REFR	Proceeds From Sale Of Common Stock And Warrants ProceedsFromSaleOfCommonStockAndWarrants	3450000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	86262	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3450000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86262	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4528186	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4566181	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	269964	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4772705	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4798150	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206524	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	549000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	38013	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	510987	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	0	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-60143	usd
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3895	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5545	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000793524
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	REFR	Proceeds From Sale Of Common Stock And Warrants ProceedsFromSaleOfCommonStockAndWarrants		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Entity File Number EntityFileNumber	000-14893
	dei	Entity Registrant Name EntityRegistrantName	RESEARCH FRONTIERS INCORPORATED
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2103466
	dei	Entity Address Address Line1 EntityAddressAddressLine1	240 CROSSWAYS PARK DRIVE
	dei	Entity Address City Or Town EntityAddressCityOrTown	WOODBURY
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11797-2033
	dei	City Area Code CityAreaCode	516
	dei	Local Phone Number LocalPhoneNumber	364-1902
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	REFR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33150396	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4798150	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	269964	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2755111	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1168450	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1016678	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80E_eus-gaap--BasisOfAccounting_zEt0F2f69Ge7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note 1. <span id="xdx_825_zR2BMVkckQw">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date. For further information, refer to the consolidated financial statements and footnotes thereto included in the Annual Report on Form 10-K relating to Research Frontiers Incorporated for the fiscal year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain amounts in the accompanying September 30, 2021 condensed consolidated statements of cash flows have been reclassified to conform to the September 30, 2022 presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zUZ1IuAEdFJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note 2. <span id="xdx_824_zIKpRxnNHaHg">Business</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research Frontiers Incorporated (“Research Frontiers” or the “Company”) operates in a single business segment which is engaged in the development and marketing of technology and devices to control the flow of light. Such devices, often referred to as “light valves” or suspended particle devices (“SPDs”), use colloidal particles that are either incorporated within a liquid suspension or a film, which is usually enclosed between two sheets of glass or plastic having transparent, electrically conductive coatings on the facing surfaces thereof. At least one of the two sheets is transparent. SPD technology, made possible by a flexible light-control film invented by Research Frontiers, allows the user to instantly and precisely control the shading of glass/plastic manually or automatically. SPD technology has numerous product applications, including SPD-Smart™ windows, sunshades, skylights and interior partitions for homes and buildings; automotive windows, sunroofs, sun visors, sunshades, rear-view mirrors, instrument panels and navigation systems; aircraft windows; museum display panels; eyewear products; and flat panel displays for electronic products. SPD-Smart light control film is now being developed for, or used in, architectural, automotive, marine, aerospace and appliance applications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has primarily utilized its cash, cash equivalents, and investments generated from sales of our common stock, proceeds from the exercise of options and warrants, and royalty fees collected to fund its research and development of SPD light valves, for marketing initiatives, and for other working capital purposes. The Company’s working capital and capital requirements depend upon numerous factors, including the results of research and development activities, competitive and technological developments, the timing and cost of patent filings, and the development of new licensees and changes in the Company’s relationships with its existing licensees. The degree of dependence of the Company’s working capital requirements on each of the foregoing factors cannot be quantified; increased research and development activities and related costs would increase such requirements; the addition of new licensees may provide additional working capital or working capital requirements; and changes in relationships with existing licensees would have a favorable or negative impact depending upon the nature of such changes. We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our SPD technology and our corporate general and administrative expenses. Our capital requirements and operations to date have been substantially funded through sales of our common stock, exercise of options and warrants and royalty fees collected. As of September 30, 2022, we had working capital of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_c20220930_zdjHSNjQr9w8" title="Working capital">5.2</span> million, cash and cash equivalents of approximately $<span id="xdx_90E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20220930_zM3sSW8guNpf" title="Cash and cash equivalents">4.8</span> million, shareholders’ equity of approximately $<span id="xdx_90F_eus-gaap--StockholdersEquity_iI_pn5n6_c20220930_zhHJCFNsJXyg" title="Shareholders' equity">5.4</span> million and an accumulated deficit of approximately $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220930_zB92sCrKyFac" title="Accumulated deficit">121.5</span> million. Our projected cash flow shortfall based on our current operations adjusted for any non-recurring cash expenses for the next 12 months is approximately $<span id="xdx_90B_ecustom--NonrecurringCashExpenses_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_z9paqFhPGLj8" title="Non-recurring cash expenses">250,000</span> to $<span id="xdx_901_ecustom--NonrecurringCashExpenses_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zdh3z1tYgkS8" title="Non-recurring cash expenses">300,000</span> per quarter. Based on our current expectations of our cash flow shortfall for the next 12 months, our working capital would support our activities in excess of the next five years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that we are unable to generate sufficient cash from our operating activities or raise additional funds, we may be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our business, operating results, financial condition and long-term prospects. The Company may seek to obtain additional funding through future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available. The eventual success of the Company and generation of positive cash flow will be dependent upon the commercialization of products using the Company’s technology by the Company’s licensees and payments of continuing royalties on account thereof. To date, the Company has not generated sufficient revenue from its licensees to fund its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Global Events:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide. As a result, the Company expects operations at its facility to continue to be affected in some capacity, as the COVID-19 virus continues to proliferate and the federal, state and local governments under which we operate continue to adopt new rules. The Company has put in place enhanced procedures, such as restricting international and domestic travel, adopting a variety of steps designed to ensure social distancing in our facilities, including working remotely where available, and increasing our cleaning and sanitizing procedures in our facilities, in an effort to protect its employees and communities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues were negatively impacted since the onset of the pandemic due to delays in manufacture of products using our technology. Most of the products using our technology are manufactured by licensees overseas in Europe and Asia who have been similarly affected by the pandemic. The disruption caused by public health crises, such as COVID-19, could result in lower levels of sale activity for products using our technology resulting in lower level of royalties owed to us from the sale of these products. The duration of the potential business disruptions and related financial impact cannot be reasonably estimated at this time, but could materially adversely affect our business, financial condition, results of operations, and cash flows. The Company increased its allowance for uncollectible royalty receivables until the collectability from certain licensees can be better ascertained in the regions affected by COVID-19.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	REFR	Working Capital WorkingCapital	5200000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4800000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5400000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121500000	usd
	REFR	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	86262	usd
	REFR	Options And Warrant Issued In Connection With Exercises OptionsAndWarrantIssuedInConnectionWithExercises	39500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	35110	shares
	REFR	Issuance Of Common Stock Options And Warrants IssuanceOfCommonStockOptionsAndWarrants	101000	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2000000.0	shares
CY2022Q3	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	2.30
CY2022Q3	REFR	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	4600000	usd
CY2022Q3	REFR	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	3450000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1500000	shares
CY2022Q3	REFR	Options And Warrant Issued In Connection With Exercises OptionsAndWarrantIssuedInConnectionWithExercises	1500000	shares
CY2022Q3	REFR	Subscription Agreements SubscriptionAgreements	1150000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2899991	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1068960	shares
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055	pure
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	54000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	160000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	54000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	217000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	222000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	56000	usd

Files In Submission

Name	View Source	Status
0001493152-22-030341-index-headers.html	Edgar Link	pending
0001493152-22-030341-index.html	Edgar Link	pending
0001493152-22-030341.txt	Edgar Link	pending
0001493152-22-030341-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
refr-20220930.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
refr-20220930_cal.xml	Edgar Link	unprocessable
refr-20220930_def.xml	Edgar Link	unprocessable
refr-20220930_pre.xml	Edgar Link	unprocessable
refr-20220930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REFR
RESEARCH FRONTIERS INC Stock $refr

2022 Q4 Form 10-Q Financial Statement

#000149315222030341 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR RESEARCH FRONTIERS INC Stock $refr

2022 Q4 Form 10-Q Financial Statement

#000149315222030341 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REFR
RESEARCH FRONTIERS INC Stock $refr